Frontotemporal Dementia (FTD) Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Frontotemporal Dementia (FTD) Epidemiology Forecast Report Coverage

Expert Market Research's “Frontotemporal Dementia (FTD) Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of frontotemporal dementia (FTD). It projects the future incidence and prevalence rates of frontotemporal dementia (FTD) cases across various populations. The study covers age, gender, and type as major determinants of the frontotemporal dementia (FTD) population. The report highlights patterns in the prevalence of frontotemporal dementia (FTD) over time and projects future trends based on multiple variables.

Frontotemporal Dementia (FTD) Understanding: Disease Overview

Frontotemporal dementia (FTD) is a progressive neurodegenerative disorder primarily affecting the frontal and temporal lobes, leading to disruptions in behavior, personality, language, and executive function. Unlike Alzheimer’s disease, memory is relatively preserved in early stages, while symptoms such as apathy, disinhibition, emotional blunting, and language impairment dominate. FTD typically presents between ages 40 and 65, making it a major cause of early-onset dementia. The condition includes behavioral variant FTD, primary progressive aphasia, and movement-related syndromes. Its course is gradual yet relentless, with significant impact on daily functioning and caregiver burden.

Frontotemporal Dementia (FTD) Epidemiology Perspective

The frontotemporal dementia (FTD) epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for Frontotemporal Dementia (FTD) epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Frontotemporal Dementia (FTD) and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Global pooled incidence of frontotemporal dementia is 2.28 per 100,000 person-years, indicating a relatively rare but impactful neurodegenerative disorder.
• Worldwide pooled prevalence is 9.17 per 100,000 population, reflecting increasing recognition and diagnostic accuracy across regions.
• In individuals under 65 years, global incidence reaches 1.84 per 100,000 person-years, while prevalence is 7.47 per 100,000, underscoring its early-onset dominance.
• Peak global diagnosis occurs at 70-72 years, suggesting broader age variability than previously characterized.
• Up to 30–40% of all FTD patients have a positive family history of a similar neurodegenerative disorder. 10–25% of cases have identifiable pathogenic mutations in major FTD-associated genes including C9orf72 repeat expansion (most common genetic cause of FTD and ALS), MAPT (microtubule-associated protein tau) and GRN (progranulin).
• Male patients demonstrate a higher global incidence, showing a consistent gender pattern across pooled international cohorts.

Read more about this report - Request a Free Sample

Country-wise Frontotemporal Dementia (FTD) Epidemiology Segment

The frontotemporal dementia (FTD) epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

In the United States, frontotemporal dementia (FTD) affects approximately 15.3 individuals per 100,000 population, reflecting its status as a rare but clinically significant neurodegenerative disorder. Age-stratified data indicate that prevalence increases with age, with lower rates in younger adults and higher occurrence among those aged 65 and above. These figures highlight the importance of early recognition and specialist care to manage disease progression and patient quality of life. Overall, FTD continues to contribute to the national dementia burden, necessitating sustained epidemiological monitoring and targeted healthcare planning.

Frontotemporal Dementia (FTD): Treatment Overview

Treatment for frontotemporal dementia is primarily symptomatic, as no disease-modifying therapy currently exists. Management focuses on controlling behavioral symptoms through SSRIs, trazodone, and structured routines. Speech-language therapy supports communication in language-variant FTD, while occupational therapy aids daily functioning and safety. Antipsychotics are used cautiously for severe agitation due to adverse effects. Multidisciplinary care, caregiver education, and environmental modification are essential components of long-term management. Emerging research is exploring tau-targeted and progranulin-based therapies, offering potential future intervention pathways, but current care remains supportive and patient-centered.

Key Questions Answered

• What are the key findings of frontotemporal dementia (FTD) epidemiology in the 8 major markets?
• What will be the total number of patients with frontotemporal dementia (FTD) across the 8 major markets during the forecast period?
• What was the country-wise frontotemporal dementia (FTD) epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of frontotemporal dementia (FTD) patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of frontotemporal dementia (FTD) during the forecast period of 2026-2035?
• What are the currently available treatments for frontotemporal dementia (FTD)?
• What are the disease risks, signs, symptoms, and unmet needs of frontotemporal dementia (FTD)?

Scope of the Frontotemporal Dementia (FTD) Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of frontotemporal dementia (FTD) based on several factors.
• Frontotemporal Dementia (FTD) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The frontotemporal dementia (FTD) report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Dementia Drugs Market

Dementia with Diabetes Drug Pipeline Analysis